Overcoming Ovarian Cancer Chemoresistance

Overcoming Ovarian Cancer Chemoresistance
Author: Goli Samimi,Christina Annunziata
Publsiher: Academic Press
Total Pages: 188
Release: 2020-11-19
ISBN 10: 0128198419
ISBN 13: 9780128198414
Language: EN, FR, DE, ES & NL

Overcoming Ovarian Cancer Chemoresistance Book Review:

Overcoming Ovarian Cancer Chemoresistance presents non-overlapping review chapters that discuss the state of the field in overcoming chemoresistance of ovarian cancer and treatment options before and following recurrence, considering the genetic makeup of the ovarian cancer patient and her tumor. With the uptake of both germline and somatic gene testing, clinicians can obtain a more comprehensive understanding of ovarian tumors and this book provides information to link the genetic makeup of a tumor (or patient) with the best available treatment. The book discusses topics such as strategies to fight chemo-resistance in ovarian cancer, circulating DNA as a monitor of response, BRCA mutations, ovarian cancer stem cells, immunotherapy and vaccines. Additionally, it brings a list of promising agents at clinical and pre-clinical stage that will impact the treatment in the near future. This book is a valuable source for cancer researchers, oncologists and several members of biomedical field who need to understand how to battle chemoresistance in ovarian cancer. Provides a comprehensive view of both biological and genetic determinants of resistance, as well as technical approaches to monitor response Discusses genetic reversions as a unique alteration and a new field of study Includes a chapter on upcoming and promising agents that are in the pre-clinical and early clinical space, to set the stage for future directions in the field

Cancer Cell Chemoresistance and Chemosensitization

Cancer Cell Chemoresistance and Chemosensitization
Author: Ajaikumar B. Kunnumakkara,Devivasha Bordoloi,Javadi Monisha
Publsiher: World Scientific
Total Pages: 329
Release: 2018
ISBN 10: 9813208570
ISBN 13: 9789813208575
Language: EN, FR, DE, ES & NL

Cancer Cell Chemoresistance and Chemosensitization Book Review:

Progress in Cancer Drug Resistance Research

Progress in Cancer Drug Resistance Research
Author: Robert A. Parsons
Publsiher: Nova Publishers
Total Pages: 223
Release: 2007
ISBN 10: 9781600218224
ISBN 13: 1600218229
Language: EN, FR, DE, ES & NL

Progress in Cancer Drug Resistance Research Book Review:

One of the main causes of failure in the treatment of cancer is the development of drug resistance by the cancer cells. The design of cancer chemotherapy has become increasingly sophisticated, yet there is no cancer treatment that is 100 percent effective against disseminated cancer. Resistance to treatment with anticancer drugs results from a variety of factors including individual variations in patients and somatic cell genetic differences in tumours, even those from the same tissue of origin. Frequently resistance is intrinsic to the cancer, but as therapy becomes more and more effective, acquired resistance has also become common.The most common reason for acquisition of resistance to a broad range of anticancer drugs is expression of one or more energy-dependent transporters that detect and eject anti-cancer drugs from cells, but other mechanisms of resistance including insensitivity to drug-induced apoptosis and induction of drug-detoxifying mechanisms probably play an important role in acquired anticancer drug resistance. Studies on mechanisms of cancer drug resistance have yielded important information on how to circumvent this resistance to improve cancer chemotherapy and have implications for pharmacokinetics of many commonly used drugs.

Biological Mechanisms and the Advancing Approaches to Overcoming Cancer Drug Resistance

Biological Mechanisms and the Advancing Approaches to Overcoming Cancer Drug Resistance
Author: Andrew Freywald,Franco Vizeacoumar
Publsiher: Academic Press
Total Pages: 308
Release: 2020-12-04
ISBN 10: 0128213116
ISBN 13: 9780128213117
Language: EN, FR, DE, ES & NL

Biological Mechanisms and the Advancing Approaches to Overcoming Cancer Drug Resistance Book Review:

Biological Mechanisms and the Advancing Approaches to Overcoming Cancer Drug Resistance, Volume 12, discusses new approaches that are being undertaken to counteract tumor plasticity, understand and tackle the interactions with the microenvironment, and disrupt the rewiring of malignant cells or bypass biological mechanism of resistance by using targeted radionuclide therapies. This book provides a unique opportunity to the reader to understand the fundamental causes of drug resistance and how different approaches are applied. It is a one-stop-shop to understand why it is so difficult to treat cancer, and why only a very few patients respond to therapy and a significant portion develop resistance. Despite a rapid development of more effective anti-cancer drugs and combination therapies, cancer remains the leading cause of lethality in the developed world. The main reason for this is the ability of heterogeneous subpopulations of tumor cells interacting with constantly evolving tumor microenvironment to resist elimination and eventually, trigger cancer relapse. In this book, experts review current concepts explaining molecular and biological mechanisms of cancer drug resistance and discussing advancing approaches for overcoming these therapeutic challenges. Provides the most updated knowledge on the mechanisms of cancer drug resistance and the emerging therapeutic approaches reviewed by experts in the field Brings detailed analyses of most important recently reported developments related to drug resistance and their relevance to overcoming it in cancer patients Discusses in-depth molecular mechanisms and novel concepts of cancer resistance to conventional and advanced therapies

Cancer Drug Resistance Research Perspectives

Cancer Drug Resistance Research Perspectives
Author: Liman S. Torres
Publsiher: Nova Publishers
Total Pages: 223
Release: 2007
ISBN 10: 9781600215728
ISBN 13: 1600215726
Language: EN, FR, DE, ES & NL

Cancer Drug Resistance Research Perspectives Book Review:

One of the main causes of failure in the treatment of cancer is the development of drug resistance by the cancer cells. The design of cancer chemotherapy has become increasingly sophisticated, yet there is no cancer treatment that is 100% effective against disseminated cancer. Resistance to treatment with anticancer drugs results from a variety of factors including individual variations in patients and somatic cell genetic differences in tumours, even those from the same tissue of origin. Frequently resistance is intrinsic to the cancer, but as therapy becomes more and more effective, acquired resistance has also become common. The most common reason for acquisition of resistance to a broad range of anticancer drugs is expression of one or more energy-dependent transporters that detect and eject anticancer drugs from cells, but other mechanisms of resistance including insensitivity to drug-induced apoptosis and induction of drug-detoxifying mechanisms probably play an important role in acquired anticancer drug resistance. Studies on mechanisms of cancer drug resistance have yielded important information about how to circumvent this resistance to improve cancer chemotherapy and have implications for pharmacokinetics of many commonly used drugs. This book presents new and important research in this field.

Drug Resistance in Colorectal Cancer Molecular Mechanisms and Therapeutic Strategies

Drug Resistance in Colorectal Cancer  Molecular Mechanisms and Therapeutic Strategies
Author: Chi Hin Cho,Tao Hu
Publsiher: Academic Press
Total Pages: 240
Release: 2020-05-24
ISBN 10: 0128199385
ISBN 13: 9780128199381
Language: EN, FR, DE, ES & NL

Drug Resistance in Colorectal Cancer Molecular Mechanisms and Therapeutic Strategies Book Review:

Drug Resistance in Colorectal Cancer: Molecular Mechanisms and Therapeutic Strategies, Volume Eight, summarizes the molecular mechanisms of drug resistance in colorectal cancer, along with the most up-to-date therapeutic strategies available. The book discusses reasons why colorectal tumors become refractory during the progression of the disease, but also explains how drug resistance occurs during chemotherapy. In addition, users will find the current therapeutic strategies used by clinicians in their practice in treating colorectal cancer. The combination of conventional anticancer drugs with chemotherapy-sensitizing agents plays a pivotal role in improving the outcome of colorectal cancer patients, in particular those with drug-resistant cancer cells. From a clinical point-of-view, the content of this book provides clinicians with updated therapeutic strategies for a better choice of drugs for drug-resistant colorectal cancer patients. It will be a valuable source for cancer researchers, oncologists and several members of biomedical field who are dedicated to better treat patients with colorectal cancer. Presents a systemic summary of molecular mechanisms for a quick and in-depth understanding Updates current trends in the field with pioneering information on drug resistance Encompasses both basic and clinical approaches for a better understanding of unsolved problems from a holistic point-of-view

Overcoming Drug Resistance in Gynecologic Cancers

Overcoming Drug Resistance in Gynecologic Cancers
Author: Anonim
Publsiher: Academic Press
Total Pages: 300
Release: 2021-05-15
ISBN 10: 9780128242995
ISBN 13: 012824299X
Language: EN, FR, DE, ES & NL

Overcoming Drug Resistance in Gynecologic Cancers Book Review:

Overcoming Drug Resistance in Gynecologic Cancers provides up-to-date information related to important gynecologic cancers and focuses on mechanisms of drug resistance, genetics, signaling, immunology, health disparities, nanotechnology, economic considerations and financial impacts. The book covers not only drug resistance but also important means to reverse resistance both in the laboratory and clinic. The book discusses topics such as lifestyle, nutrition and risk of gynecologic cancers, the financial impact of drug resistance, chemosensitizing agents and targeted therapies in cervical, endometrial and ovarian cancer, immunotherapy to overcome drug resistance, and genetic polymorphisms in gynecologic cancers. Additionally, it discusses ethnic and racial health disparity perspectives and future developments in chemosensitizing activities to reverse drug resistance in gynecologic cancers. It is a valuable resource for cancer researchers, oncologists, clinicians and other biomedical field members who are interested in new approaches to improve chemotherapy outcome in patients with gynecologic cancers. Provides a comprehensive resource with all the details needed for readers to understand and follow information Encompasses schematics, diagrams and flow charts in all chapters to help readers easily follow critical information Presents tables and figures especially developed to summarize the information with appropriate statistical rigor and to show details of clinical specimens such as pathological, radiological characteristics, and/or laboratory biomarkers

Ovarian Cancer

Ovarian Cancer
Author: George Coukos,Andrew Berchuck,Robert Ozols
Publsiher: Springer Science & Business Media
Total Pages: 308
Release: 2008-06-06
ISBN 10: 0387689699
ISBN 13: 9780387689692
Language: EN, FR, DE, ES & NL

Ovarian Cancer Book Review:

Aegean Conferences is an independent, nonprofit, educational organization directed and managed by the scientific community. The board is made up of nine researchers/scientists in various disciplines from Harvard, Brown, University of Pennsylvania, UCSD, Princeton, Biovista and the Foundation for Biomedical Research Academy of Athens. The board both invites and approves unsolicited proposals for Conferences in all fields of Science, Engineering, Arts, and Humanities. The purpose of the Conferences is to bring together individuals with common interests to examine the emerging and most advanced aspects of their particular field. The Symposium on Ovarian Cancer: State of the Art and Future Directions intends to bring together international experts interested in the development of novel diagnostic, prognostic and therapeutic tools for ovarian cancer. The meeting will function as a think tank where clinicians, translational and basic scientists, and parties from the biotechnology and pharmaceutical industry will get together to review recent advances in clinical research and translational science in ovarian cancer and define areas of future research opportunities and priorities.

Drug Resistance in Oncology

Drug Resistance in Oncology
Author: S. Bernal
Publsiher: CRC Press
Total Pages: 416
Release: 1997-08-21
ISBN 10: 9781420002096
ISBN 13: 1420002090
Language: EN, FR, DE, ES & NL

Drug Resistance in Oncology Book Review:

This timely new reference integrates the latest clinical results and laboratory studies on the resistance of specific cancers to chemotherapeutic drugs-covering drug resistance in lung, breast, ovary, and colon cancer as well as hematological malignancies.

Drug Resistance in Cancer Therapy

Drug Resistance in Cancer Therapy
Author: Robert F. Ozols
Publsiher: Springer Science & Business Media
Total Pages: 210
Release: 2012-12-06
ISBN 10: 1461316014
ISBN 13: 9781461316015
Language: EN, FR, DE, ES & NL

Drug Resistance in Cancer Therapy Book Review:

Where do you begin to look for a recent, authoritative article on the diagnosis or management of a particular malignancy? The few general oncology textbooks are generally out of date. Single papers in specialized journals are informative but seldom comprehensive; these are more often preliminary reports on a very limited number of patients. Certain general journals frequently publish good in-depth reviews of cancer topics, and published symposium lectures are often the best overviews available. Unfor tunately, these reviews and supplements appear sporadically, and the reader can never be sure when a topic of special interest will be covered. Cancer Treatment and Research is a series of authoritative volumes that aim to meet this need. It is an attempt to establish a critical mass of oncology literature covering virtually all oncology topics, revised frequently to keep the coverage up to date, easily available on a single library shelf or by a single personal subscription. We have approached the problem in the following fashion: first, by dividing the oncology literature into specific subdivisions such as lung can cer, genitourinary cancer, and pediatric oncology; second, by asking emi nent authorities in each of these areas to edit a volume on the specific topic on an annual or biannual basis. Each topic and tumor type is covered in a volume appearing frequently and predictably, discussing current diagnosis, staging, markers, all forms of treatment modalities, basic biology, and more.

Ovarian Cancer

Ovarian Cancer
Author: Omer Devaja,Andreas Papadopoulos
Publsiher: BoD – Books on Demand
Total Pages: 364
Release: 2018-10-24
ISBN 10: 1789843332
ISBN 13: 9781789843330
Language: EN, FR, DE, ES & NL

Ovarian Cancer Book Review:

Ovarian cancer management is a rapidly changing field with new treatment agents available as a result of a greater understanding of the pathogenesis of this disease. In addition, both surgical and chemotherapeutic treatment strategies are evolving to maximise response in this disease. This book brings together leading specialists from around the world to discuss and outline a variety of new concepts in ovarian cancer, ranging from molecular biology and genetics through screening to both surgical and chemotherapeutic management.

Encyclopedia of Cancer

Encyclopedia of Cancer
Author: Manfred Schwab
Publsiher: Springer Science & Business Media
Total Pages: 3235
Release: 2008-09-23
ISBN 10: 3540368477
ISBN 13: 9783540368472
Language: EN, FR, DE, ES & NL

Encyclopedia of Cancer Book Review:

This comprehensive encyclopedic reference provides rapid access to focused information on topics of cancer research for clinicians, research scientists and advanced students. Given the overwhelming success of the first edition, which appeared in 2001, and fast development in the different fields of cancer research, it has been decided to publish a second fully revised and expanded edition. With an A-Z format of over 7,000 entries, more than 1,000 contributing authors provide a complete reference to cancer. The merging of different basic and clinical scientific disciplines towards the common goal of fighting cancer makes such a comprehensive reference source all the more timely.

Ovarian Cancer 3

Ovarian Cancer 3
Author: Frank Sharp,Peter Mason,Tony Blackett,Jonathan Berek
Publsiher: Springer
Total Pages: 390
Release: 2012-12-06
ISBN 10: 1475701365
ISBN 13: 9781475701364
Language: EN, FR, DE, ES & NL

Ovarian Cancer 3 Book Review:

The Helene Harris Memorial Trust has become recognized as providing one of the most important international fora for the presentation of research in ovarian cancer. Four biennial meetings have taken place, the most recent of which was held between May 11-14, 1993, in Toronto, Canada. This forum has grown in stature from its inception in 1987 and has brought together interdisciplinary clinical and scientific researchers from around the world who are endeavouring to perform 'cutting edge' studies in the field. The assembled group of presti gious investigators met on this occasion to present their data, to exchange ideas, and to arrange collaborations with the goal of developing new means of detection, treatment and cure of ovarian cancer. The incentive for the establishment of the Trust and its international forum was the prema ture loss through ovarian cancer of Helene Harris, the wife of Mr John Harris. Mr Harris and the Trustees looked for a meaningful way to honour the memory of Helene and to advance the noble cause of gaining an increase in the scientific knowledge of the subject. For those of us who spend most of our waking hours assisting patients and their families who are devastated by this disease, the Trust's generosity provides inspiration, hope and the opportunity for their practical application in a unique professional forum.

Gynecologic Oncology

Gynecologic Oncology
Author: Robert F. Ozols
Publsiher: Taylor & Francis
Total Pages: 387
Release: 1998
ISBN 10: 9780792380702
ISBN 13: 0792380703
Language: EN, FR, DE, ES & NL

Gynecologic Oncology Book Review:

Text focusing primarily on ovarian cancer. Explores advances in cytoreductive surgery, problems in screening, new drugs, chemotherapy, hereditary basis for gynecologic malignancies, molecular genetics, molecular biology, and new biologic therapies. For researchers and pathologists, surgeons, chemotherapists, and practitioners.

Advances in Epithelial Ovarian Cancer Model Systems Microenvironmental Influences Therapy and Origins

Advances in Epithelial Ovarian Cancer  Model Systems  Microenvironmental Influences  Therapy  and Origins
Author: Viive Maarika Howell,Ben Davidson,TIAN-Li WANG,Christina Annunziata
Publsiher: Frontiers Media SA
Total Pages: 329
Release: 2016-02-03
ISBN 10: 2889197697
ISBN 13: 9782889197699
Language: EN, FR, DE, ES & NL

Advances in Epithelial Ovarian Cancer Model Systems Microenvironmental Influences Therapy and Origins Book Review:

This eBook provides a compendium of the current state-of-the-art in research tools for, and understanding of, the critical research areas in epithelial ovarian cancer (EOC) with a strong emphasis on (HG-SOC). Research areas covered include therapy response and development, microenvironmental influences and the etiology and progression of EOC. Ten articles detail established and novel in vivo and in vitro model systems. These include primary and immortalized cell culture in 2D and 3D as well as genetically engineered, transgenic, spontaneous, syngeneic, classical xenograft and patient derived xenograft mouse models. The generation of genetically engineered mouse models of HG-SOC has been a major dilemma as models with the oncogenic aberrations common in the human malignancy do not accurately recapitulate HG-SOC. Conversely, commonly used HG-SOC cell lines have been found to not harbor the expected genetic changes. These issues as well as the rapid acceptance of patient derived xenograft models are reviewed. Five articles discuss different aspects of the tumor microenvironment including its role in therapy resistance, disease progression and metastasis. Mutation of BRCA1/2 continues to be the best defined risk factor for HG-SOC. Three articles discuss BRCA-loss in the context of disease development, targeted therapies and changes in preventative measures proposed for mutation carriers in light of the recent advances in knowledge regarding the origins of this malignancy. An image of HG-SOC with reduced BRCA1 expression is featured on the cover (image by VM Howell). A major clinical issue for patients with HG-SOC is the development of therapy resistance. Five articles focus on therapy resistance and different ways to overcome resistance. Overall, this eBook is an outstanding resource to aid researchers design their programs of research and determine the most appropriate and up-to-date EOC model systems to address their research questions.

Drug Resistance in Cancer Cells

Drug Resistance in Cancer Cells
Author: Kapil Mehta,Zahid H. Siddik
Publsiher: Springer Science & Business Media
Total Pages: 363
Release: 2009-06-12
ISBN 10: 9780387894454
ISBN 13: 0387894454
Language: EN, FR, DE, ES & NL

Drug Resistance in Cancer Cells Book Review:

It was estimated that in 2008, 1,437,180 patients would receive a new cancer diagnosisand 565,650individualswould die of cancer (Jemal et al. 2008).Since the vast majority of patients dying of cancer will have had anticancer therapy, both c- ventional chemotherapy and novel targeted therapy, it can be concluded that these patients are dying with drug resistant cancer. The term multidrug resistance is also apt – in that these patients die after having undergone multiple rounds of different and structurally unrelated cancer therapies. However, for some, the concept of m- tidrug resistance is a worn out idea, stemming from disappointment with the drug resistancereversalstrategiesthatwerecarriedoutinthe1990susingpumpinhibitors to block drug resistance mediated by P-glycoprotein, product of the MDR-1 gene. However, if one takes the larger de?nition – multidrug resistance as simultaneous resistance to multiple structurally unrelated anticancer therapies – its existence c- not be denied. The purpose of this book is to explore new concepts related to drug resistance in cancer, including resistance to the new molecularly targeted agents. Perhaps new terminology is needed for resistance that occurs following therapy with the targeted agents: Novel Targeted Agent Resistance (NTR). Alternatively, we can return to the original de?nition of multidrug resistance as simply the res- tance to multipleagents that occurs in the course of normalcancer progression.This resistance is likely to be mediated by many factors.

Ovarian Cancer

Ovarian Cancer
Author: Robert F. Ozols,American Cancer Society
Publsiher: PMPH-USA
Total Pages: 246
Release: 2003
ISBN 10: 9781550090963
ISBN 13: 1550090968
Language: EN, FR, DE, ES & NL

Ovarian Cancer Book Review:

"Featuring more than 300 illustrations, the text covers pathology, biology, epidemiology, genetics, and screening through surgical management, the latest in chemotherapeutic regimens, and finally, palliative care"--P. [4] of cover.

Cancer Drug Resistance

Cancer Drug Resistance
Author: Thomas C. Hall
Publsiher: Anonim
Total Pages: 235
Release: 1986
ISBN 10:
ISBN 13: UOM:39015011479253
Language: EN, FR, DE, ES & NL

Cancer Drug Resistance Book Review:

Ovarian Cancer New Insights for the Healthcare Professional 2011 Edition

Ovarian Cancer  New Insights for the Healthcare Professional  2011 Edition
Author: Anonim
Publsiher: ScholarlyEditions
Total Pages: 274
Release: 2012-01-09
ISBN 10: 1464900604
ISBN 13: 9781464900600
Language: EN, FR, DE, ES & NL

Ovarian Cancer New Insights for the Healthcare Professional 2011 Edition Book Review:

Ovarian Cancer: New Insights for the Healthcare Professional: 2011 Edition is a ScholarlyEditions™ eBook that delivers timely, authoritative, and comprehensive information about Ovarian Cancer. The editors have built Ovarian Cancer: New Insights for the Healthcare Professional: 2011 Edition on the vast information databases of ScholarlyNews.™ You can expect the information about Ovarian Cancer in this eBook to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of Ovarian Cancer: New Insights for the Healthcare Professional: 2011 Edition has been produced by the world’s leading scientists, engineers, analysts, research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors at ScholarlyEditions™ and available exclusively from us. You now have a source you can cite with authority, confidence, and credibility. More information is available at http://www.ScholarlyEditions.com/.

Intraperitoneal Therapy for Ovarian Cancer

Intraperitoneal Therapy for Ovarian Cancer
Author: David Alberts,Mary C. Clouser,Lisa M. Hess
Publsiher: Springer Science & Business Media
Total Pages: 153
Release: 2010-08-24
ISBN 10: 9783642121302
ISBN 13: 3642121306
Language: EN, FR, DE, ES & NL

Intraperitoneal Therapy for Ovarian Cancer Book Review:

Intraperitoneal chemotherapy is increasingly being used as first-line treatment for ovarian cancer. Nevertheless, it is difficult for the oncologist to find a definitive text that documents both the fundamental methods required to optimize therapy and the up-to-date results of phase I, II, and III clinical trials. With this in mind, the editors of Intraperitoneal Chemotherapy have assembled a team of highly experienced clinicians and researchers to cover every aspect of the subject. The topics addressed include treatment principles, patient, drug, and catheter selection, administration guidelines, the role of hyperthermia, supportive care requirements, novel drugs, and the most recent results of clinical trials. This book will be an invaluable source of information for both practicing clinical oncologists and oncologists in training.